Serious GMP Deficiencies at Italian Sterile Manufacturer
Recommendation

16-18 June 2026
Good Engineering Practice for Pharmaceutical Companies and Suppliers
On the basis of a GMP inspection performed in May 2018 at an Italian sterile manufacturer, the Italian authority (AIFA) recommended the recall of batches and issued a GMP non-compliance report.
In total, the Italian authority found nine serious deficiencies in the area of contamination control of premises and equipment. Also the personnel and material flows were criticised. Moreover, aseptic processing in the production area as well as the microbiological quality control and deviation management gave reasons for complaints. The aseptic manufacturing in question concerns a lyophilized API. The grave situation here is that the Italian manufacturer performs this manufacturing step as a contract manufacturer for several pharmaceutical companies. Now, the AIFA recommends suspending the manufacturing authorisation for the lyophilizing process and recalling the batches concerned insofar there is no risk of shortage. With this non-compliance report the national GMP authorities have got the information and can take the necessary measures.
According to the Italian authority, the manufacture of non-sterile APIs and medicinal finished products is not affected. You can find the report of the Italian authority (AIFA) in the EU EudraGMDP database.
Related GMP News
08.04.2026Deficiencies in Equipment Design lead to Warning Letter
01.04.2026Rouging in pharmaceutical Water and Pure Steam Systems: Causes, Effects and Control Measures
18.03.2026HVAC Systems: Is there a Difference between Mixed Air and Recirculation Air Operation?
04.03.2026Warning Letter to US Contract Manufacturer of OTC Drugs due to Cross-Contamination Risk
04.03.2026Warning Letter following Complaints about Tablets
04.03.2026What does the FDA expect regarding Facility Maintenance?


